• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Efficacy and Safety Trials Results of Complement Inhibitors

Opinion
Video

Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management.

Video content above is prompted by the following:

Several complement inhibitors have been approved since eculizumab, including ravulizumab, a long-acting C5 inhibitor; danicopan, a factor D inhibitor; pegcetacoplan, a complement C3 inhibitor; and iptacopan, a complement factor B inhibitor. Please discuss the efficacy and safety results from the pivotal trials for each of these treatments.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
4 experts in this video
4 experts in this video
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.